OncLive TV

Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

August 30th 2021

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

August 30th 2021

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Dr. Patil on Key Developments With Targeted Therapy in Lung Cancer

August 26th 2021

Pradnya D. Patil, MD, FACP, discusses recent developments with targeted therapies in lung cancer.

Dr. Abida on Future Research Directions in mCRPC

August 26th 2021

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Chu on Ongoing Efforts to Address Disparities in Lung Cancer

August 26th 2021

Edward Chu, MD, MMS, discusses ongoing efforts to address disparities in lung cancer at Montefiore and Albert Einstein College of Medicine.

Dr. Garg on the Emergence of Antiandrogen Agents in nmCRPC

August 25th 2021

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

Dr. Goldman on Key Takeaways From the CASPIAN Trial in Frontline ES-SCLC

August 25th 2021

Jonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.

Dr. Dietrich on Navigating the NSCLC Treatment Landscape

August 25th 2021

Martin Dietrich, MD, PhD, shares how he navigates the non–small cell lung cancer (NSCLC) treatment landscape.

Dr. Eskander on the Utility of Lymphadenectomy in Endometrial Cancer

August 25th 2021

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate Cancer

August 24th 2021

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

Dr. Pecot on Addressing Mechanisms of Resistance With New Targeted Therapies in NSCLC

August 24th 2021

Chad V. Pecot, MD, discusses addressing mechanisms of resistance with new targeted therapies in non–small cell lung cancer.

Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

August 24th 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian Cancer

August 24th 2021

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Dr. Slovin on Selecting Among Available Treatment Options in mCSPC

August 24th 2021

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Dr. Van Tine on Outcomes With Catequentinib in Synovial Sarcoma

August 24th 2021

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Dr. Fakih on Efficacy With Regorafenib Plus Nivolumab in Metastatic CRC

August 23rd 2021

Marwan Fakih, MD, discusses efficacy reported with regorafenib plus nivolumab in patients with mismatch repair–proficient and microsatellite stable metastatic colorectal cancer.

Dr. Stevenson on Ongoing Research Efforts in ES-SCLC

August 23rd 2021

James Stevenson, MD, medical oncologist and hematologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

Dr. Shore on the Utility of PSMA PET Imaging Agent Piflufolastat F 18 for Prostate Cancer

August 23rd 2021

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Dr. Litton on the Safety of Neoadjuvant Talazoparib in HER2-Negative Breast Cancer

August 23rd 2021

Jennifer Litton, MD, discusses the safety of talazoparib (Talzenna) in the neoadjuvant treatment of patients with germline BRCA1/2-positive, early-stage HER2-negative breast cancer.

Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer

August 23rd 2021

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.